To the full analysis
Pacira BioSciences stock: growth
PCRXPacira BioSciences reported $726.41M in revenue for fiscal 2025, up 3.6% on the prior year, up 11.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
26.2%
per year from 2008 to 2025, per share −2.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2008 | |
|---|---|---|---|
| Revenue | 11.1% | 11.3% | 26.2% |
| Revenue per share | 10.1% | 9.1% | −2.8% |
| Earnings | −45.4% | 14.3% | no data |
| Earnings per share | −45.8% | 12.3% | no data |
| Free cash flow | 28.4% | no data | no data |
| Free cash flow per share | 27.2% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2008 | $13.93M | −$41.86M | −$35.03M |
| 2009 | $15.01M | −$31.71M | −$26.35M |
| 2010 | $14.56M | −$27.15M | −$31.65M |
| 2011 | $15.69M | −$43.33M | −$37.17M |
| 2012 | $39.08M | −$52.28M | −$88.39M |
| 2013 | $85.55M | −$63.91M | −$56.01M |
| 2014 | $197.67M | −$13.72M | $3.58M |
| 2015 | $249M | $1.86M | −$12.27M |
| 2016 | $276.37M | −$37.95M | $8.74M |
| 2017 | $286.63M | −$42.61M | −$1.48M |
| 2018 | $337.28M | −$471K | $34.36M |
| 2019 | $421.03M | −$11.02M | $60.36M |
| 2020 | $429.65M | $145.52M | $39.23M |
| 2021 | $541.53M | $41.98M | $79.85M |
| 2022 | $666.82M | $15.91M | $115.2M |
| 2023 | $674.98M | $41.96M | $139.49M |
| 2024 | $700.97M | −$99.56M | $178.75M |
| 2025 | $726.41M | $7.03M | $136.66M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.